Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spartalizumab plus mDCF chemotherapy and radiotherapy in metastatic squamous cell anal carcinoma
2021-002563-22Phase 2Active
- Sponsor
- CHU de Besançon
- Start
- May 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of spartalizumab in anal squamous cell carcinoma (SCCA), sponsored by CHU de Besançon. Primary endpoint: Progression-free survival rate at 1 year. Started May 2021; status: active.
02
Drugs
spartalizumab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2021-002563-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002563-22.